1.Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology. 2010;17(6):1471–4.
2.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(1):7–30.
3.Otunctemur A, Dursun M, Besiroglu H, Ozer K, Horsanali M, Ozbek E. Clinical Significance of Preoperative Neutrophil - to - Lymphocyte Ratio in Renal Cell Carcinoma2016. 678–84 p.
4.Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA: a cancer journal for clinicians. 2012;62(1):10–29.
5.Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, et al. Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma. Journal of Clinical Oncology. 2002;20(23):4559–66.
6.Park YH, Baik KD, Lee YJ, Ku JH, Kim HH, Kwak C. Late recurrence of renal cell carcinoma >5 years after surgery: clinicopathological characteristics and prognosis. BJU International. 2012;110(11b):E553-E8.
7.Kim SP, Weight CJ, Leibovich BC, Thompson RH, Costello BA, Cheville JC, et al. Outcomes and Clinicopathologic Variables Associated With Late Recurrence After Nephrectomy for Localized Renal Cell Carcinoma. Urology. 2011;78(5):1101–6.
8.Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.
9.el-Hag A, Clark RA. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. Journal of immunology (Baltimore, Md: 1950). 1987;139(7):2406–13.
10.Petrie HT, Klassen LW, Kay HD. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. Journal of immunology (Baltimore, Md: 1950). 1985;134(1):230–4.
11.Kokcu A, Kurtoglu E, Celik H, Tosun M, Malatyalıoglu E, Ozdemir AZ. May the platelet to lymphocyte ratio be a prognostic factor for epithelial ovarian cancer? Asian Pac J Cancer Prev. 2014;15(22):9781–4.
12.Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Journal of the National Cancer Institute. 2014;106(6):dju124.
13.Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. British journal of cancer. 2014;111(3):452–60.
14.Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. Journal of surgical oncology. 2005;91(3):181–4.
15.Personeni N, Giordano L, Abbadessa G, Porta C, Borbath I, Daniele B, et al. Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197–215 second-line study for advanced hepatocellular carcinoma. Oncotarget. 2017;8(9):14408–15.
16.Xue T-C, Zhang L, Xie X-Y, Ge N-L, Li L-X, Zhang B-H, et al. Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Primary Liver Cancer: A Meta-Analysis. PLOS ONE. 2014;9(5):e96072.
17.Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim YT, et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer immunology, immunotherapy: CII. 2009;58(1):15–23.
18.Wang X, Su S, Guo Y. The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget. 2017;8(48):84506–14.
19.Viers BR, Houston Thompson R, Boorjian SA, Lohse CM, Leibovich BC, Tollefson MK. Preoperative neutrophil-lymphocyte ratio predicts death among patients with localized clear cell renal carcinoma undergoing nephrectomy. Urologic oncology. 2014;32(8):1277–84.
20.Seda C, Salas A, Sánchez CG, Blasco J, García I, Sánchez J, et al. Thrombocytosis and hematocrit as prognostic factors in renal carcinoma. Arch Esp Urol. 2011;64(9):883–90.
21.Lee S-M, Russell A, Hellawell G. Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma. Korean journal of urology. 2015;56(11):749–55.
22.Kemal Y, Yucel I, Ekiz K, Demirag G, Yilmaz B, Teker F, et al. Elevated serum neutrophil to lymphocyte and platelet to lymphocyte ratios could be useful in lung cancer diagnosis. Asian Pacific journal of cancer prevention: APJCP. 2014;15(6):2651–4.
23.Hu K, Lou L, Ye J, Zhang S. Prognostic role of the neutrophil–lymphocyte ratio in renal cell carcinoma: a meta-analysis. BMJ open. 2015;5(4):e006404.
24.Kilincalp S, Çoban Ş, Akinci H, Hamamcı M, Karaahmet F, Coşkun Y, et al. Neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and mean platelet volume as potential biomarkers for early detection and monitoring of colorectal adenocarcinoma. European Journal of Cancer Prevention. 2015;24(4):328–33.
25.Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiology and Prevention Biomarkers. 2014;23(7):1204–12.
26.Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436.
27.Wang Z, Peng S, Wang A, Xie H, Guo L, Jiang N, et al. Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma. Clinica Chimica Acta. 2018;480:166–72.
28.Luo Y, She D-L, Xiong H, Fu S-J, Yang L. Pretreatment neutrophil to lymphocyte ratio as a prognostic predictor of urologic tumors: a systematic review and meta-analysis. Medicine. 2015;94(40).
29.Arda E, Yuksel I, Cakiroglu B, Akdeniz E, Cilesiz N. Valuation of neutrophil/lymphocyte ratio in renal cell carcinoma grading and progression. Cureus. 2018;10(1).
30.Vano Y-A, Oudard S, By M-A, Têtu P, Thibault C, Aboudagga H, et al. Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients. PloS one. 2018;13(4):e0195042.
31.Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. The Journal of urology. 2012;187(2):411–7.
32.Nunno VD, Mollica V, Gatto L, Santoni M, Cosmai L, Porta C, et al. Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis. Immunotherapy. 2019;11(7):631–43.